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Introduction
Detection of EGFR activating mutations and Anaplastic 
Lymphoma Kinase (ALK) rearrangements has become 
a standard of care for patients with adenocarcinoma 
of primary lung origin. ALK protein is a member of 
the Insulin receptor family of tyrosine kinases; ALK 
gene was discovered in 1994 in a subset of Anaplastic 
Large-Cell Lymphomas (ALCL) carrying t(2; 5) (p23;q35) 
translocation (Soda et al., 2007). ALK receptor protein is 
not expressed in the normal lung but gets activated by the 
echinoderm microtubule-associated protein like 4(EML4)- 
Anaplastic Lymphoma Kinase gene fusion which 
occurs in approximately 3-5% of the patients with lung 
adenocarcinoma (Soda et al., 2007; Chiarle et al., 2008; 
Rodig et al., 2009). Rearrangements of the ALK gene are 
associated with patients of younger age, non-smokers, and 
adenocarcinoma with signet cells (Rodig et al., 2009).
Two main diagnostic tests being carried out to assess 
ALK gene status are Fluorescent in situ hybridization 
(FISH) analysis and the immunohistochemical technique 
(IHC). FISH works with a breakapart probe for ALK 
receptor gene analysis to determine its status in lung 
adenocarcinoma (Camidge et al., 2012; Shaw et al., 2013; 
Solomon et al., 2014). However FISH is technically 
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challenging, expensive and the required apparatus is 
not readily available in routine diagnostic laboratories 
along with specialized expertise (Rodig et al., 2009; 
Camidge et al., 2010; Mino-Kenudson et al., 2010). 
Immunohistochemical methods, on the other hand, readily 
available in most Pathology labs are much cheaper and 
easy to interpret. Although ALK-FISH is a Food and 
Drug Administration (FDA) approved method to detect 
fusion gene, a proportion of ALK-positive tumors show 
no detectable rearrangements, whereas on subsequent they 
were ALK IHC positive tumors and showed a remarkable 
response to receiving Crizotinib treatment (Peled et al., 
2012; Sun et al., 2012; Ren et al., 2014; Shan et al., 2015). 
However the lack of standardization of the IHC technique 
as the primary diagnostic test has made it challenging to 
make an early diagnosis of the disease and evaluate a 
broader range of available treatment options. Crizotinib 
has been approved by the FDA for treatment for patients 
with advanced or metastatic non-small cell lung carcinoma 
(Malik et al., 2014). ALK rearrangement identification is 
an important procedure for lung cancers as they have a 
50-60% response rate to Crizotinib and similar treatment 
options such as other ALK tyrosine kinase inhibitors 
leading to a better survival rate. The therapeutic options 
are chosen on the basis of genetic signature EML-ALK 
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translocation. Although, FISH technique is the preferred 
diagnostic method, however, for a broad implementation 
it is not optimal due to its technical and financial reasons, 
whereas IHC techniques would be a promising diagnostic 
method applicable for routine clinical practice in the near 
future due to its several advantages from being easily 
accessible to being more affordable and practicable.
Hence the purpose of this study was to reevaluate 
previously diagnosed cases of lung adenocarcinoma tested 
for ALK by FISH method using IHC testing and to further 
establish the role of IHC reliable substitute for primary 
screening of ALK rearrangements.
Materials and Methods
Sampling
The data of 64 patients was included who were 
diagnosed as adenocarcinoma of primary lung origin 
both in lung as well as in metastatic setting and tested 
for EGFR mutations and ALK rearrangements in our lab 
between 2015-2017. These patients were first analyzed 
for EGFR mutation by a commercial Real-time PCR 
kit. Then the EGFR negative samples were subjected 
to ALK mutation analysis by FISH technique followed 
by immunohistochemistry for ALK protein. In the case 
of metastasis, only those cases were recruited where 
confirmation of lung as the primary site of cancer was 
established.
EGFR mutation analysis
Depending upon the size of the tissue, 2-5 sections of 5 
µM thickness of FFPE specimen were cut and placed in 1.5 
ml microfuge tubes. DNA extraction and multiplex PCR 
was performed using Cobas EGFR mutation detection kit 
and the Cobas z480 Real-time PCR instrument (Roche 
Molecular Systems, Branchburg, NJ, USA); following the 
standard package insert protocol. Cobas EGFR Mutation 
Test uses allele-specific polymerase chain reaction (AS-
PCR) and can detect 43 different mutations in four exons 
(18-21) of EGFR gene, including several point mutations, 
deletions, and insertions. 
FISH for ALK rearrangement
Paraffin sections from patients’ tumor block ranging 
4-6 µm in thickness were deparaffinized in xylene before 
being dehydrated with graded ethanol. The sections were 
incubated in 0.2N HCl for 20min, washed and immersed 
in protease solution for 30min and finally fixed in 10% 
buffered formalin. ALK probe cocktail (5’ 442 kb and 3’ 
300 kb) purchased from Abbott Diagnostics (Chicago, IL, 
USA) were co-denatured at 73˚C for 7 min in Thermobrite 
(Abbott Molecular, Chicago, IL, USA) and further 
incubated overnight at 37˚C. Next day slides were washed 
in 2X SSC/0.3% NP-40 solution twice and counterstained 
with DAPI. Fluorescent signals were observed and scored 
under a Nikon Eclipse 90i (Nikon Inc., Melville, NY, 
USA) upright fluorescent microscope and 100 nuclei 
were observed.
Immunohistochemistry for ALK
IHC was performed in automated DAKO system. 
Briefly, 5 µm tumor tissue sections were deparaffinized at 
60oC for 30-60 min followed by incubations in xylene and 
graded ethanol. Antigens were unmasked as recommended 
by the manufacturer. Primary antibody against ALK 
(monoclonal mouse anti-human, CD246 from DAKO) was 
incubated at room temperature for 30 mins. Subsequent 
to multiple washes, tissues were blocked, and slides were 
incubated with a secondary antibody linked with HRP 
(DAKO, Denmark). Incubation in DAB, HRP substrate, 
revealed antigenic localization. After counterstaining 
with Mayer’s Haematoxylin, tissues were dehydrated and 
cover-slipped. Appropriate positive and negative controls 
were included in each run. The slides were assessed 
independently by two histopathologists, and scoring was 
done according to the reported method (To et al., 2013).
Results
EGFR mutation analysis
Out of 64 patients 14 (21.8%) came out to be positive 
for EGFR mutations. The mutation test covers exon-18 
to 24 of the EGFR gene. The results showed that six 
patients had a deletion in exon-19. Furthermore, two 
patients carried compound mutations in the following 
combination S768I (Serine is replaced by Isoleucine, 
exon-20) and L858R (Leucine is replaced by Arginine, 
exon-21) and other showed combination T790M (change 
from Threonine to Methionine, exon- 20) and G719X 
(exon-18). Six patients were positive for point mutation 
L858R in exon-21. 
ALK analysis by FISH
Breakapart probes labeled with red and green 
a) b)
Figure 1. A Representative Image of ALK Negative (a) and Positive (b) Lung Adenocarcinoma. Separated Red and 
Green signals indicate ALK gene rearrangement  
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half of the cases tend to progress towards a second-site 
mutation in EGFR kinase domain and more than 90% 
is the change of thymine to cytosine at 2639 position in 
exon 20. (Kwak et al., 2005; Balak et al., 2006; Kosaka et 
al., 2006). Our study showed the similar results to these 
studies in EGFR mutational analysis which provided the 
insight into the eligibility of patients for TKIs. Compound 
mutations were also observed which showed the increased 
resistance towards the TKIs. 
In 2007, Soda et al., (2007) reported a fusion gene 
consisted of portions of EML4 (N terminal segment) 
and ALK( kinase domain) as a result of small inversion 
within chromosome 2p. The EML4-ALK translocation 
represents a new subgroup of lung adenocarcinoma 
patients who respond positively to ALK inhibitors. Recent 
studies suggest that presence of EML4-ALK fusion varies 
from 3-6% depending on the factors like ethnicity and 
detection methods (Takeuchi et al., 2008; Takeuchi et al., 
2009). According to different studies genetic alterations 
in EGFR, KRAS, and ALK do not co-exist (Gainor et 
al., 2013). The results of this study concord with the 
published reports showing that the mutations of EGFR 
and ALK are mutually exclusive. Moreover, in our study, 
the overall ALK positivity was 14% which is higher than 
the reported data where, limited sample size remained 
a constraint. As ALK mutations mostly consists of 
intrachormosomal deletion and inversion so the diagnosis 
for ALK rearrangement requires FISH, RT-qPCR and 
ISH where FISH being the gold standard in diagnostics 
(Gainor et al., 2013). 
Both techniques have pros and cons and recent 
publications in order to find the association of both 
the techniques in ALK detection have discussed the 
discordances (Boland et al., 2009). FISH has been 
approved by FDA as the method of choice for patient 
selection in clinical trials. The breakapart probe allows 
detection of rearrangements without the specificity of 
breakpoint. In addition, nonspecific signal separation 
could not be attributed to cells without rearrangement 
which increases the possibility of false results and 
intraobserver variability. Moreover, FISH requires 
specialized laboratory equipment and techniques, 
expert interpretation, relatively high costs, and a longer 
turnaround time and fluorescent signals rapidly fades 
away with time (Camidge et al., 2010). An alternative 
diagnostic method to FISH is IHC, which recently has 
been studied extensively for its usability in routine testing. 
The efficacy of IHC detection depends on various factors 
like tissue preparation, scoring system (H-score), type and 
affinity of antibody and the sensitivity of detection system. 
IHC was shown to be specific but not sensitive in earlier 
studies which could be attributed to the low transcriptional 
activity or instability of EML4 in cells (Martelli et al., 
2009; Murakami et al., 2012). In a study conducted by 
Sholl et al. found one out of 15 ALK-positive specimens 
tested by FISH method was falsely negative and two were 
false positives after being reanalyzed using IHC, further 
highlighting the importance of this testing technique (Sholl 
et al., 2013). In our study four of the FISH positive ALK 
samples showed strong cytoplasmic staining in IHC and 
fluorochromes were used to analyze ALK rearrangement 
at 2p23. The red probe was telomeric probe (3’) and the 
green probe was centromeric probe (5’). Intact gene would 
exhibit fused signal of yellow color (Figure 1a), else the 
signal would split in to green and red in case of inversion 
of the region (Figure 1b), and either of the signals would 
be lost if a deletion occurs. A total of 100 nuclei were 
observed and a rearrangement was considered positive if 
observed in more than 15% of the nuclei and signals were 
at least two diameters apart. Out of 50 patients, 7 (14%) 
patients were found to have ALK gene rearrangements.
ALK by IHC
ALK was checked on all the samples which were 
FISH positive along with a subset of negative samples. 
According to the published criteria, IHC scores of 0 
and 1+ were chosen as negative and scores of 2+ or 3+ 
as positive. Out of seven samples 4 showed diffused 
cytoplasmic staining and one sample came out to be 
weak positive (+1) which was considered as negative and 
other two samples were negative for ALK rearrangement 
staining (Figure 2). 
Discussion
This study was done to determine the presence of 
EGFR mutations with ALK mutations and association of 
FISH and IHC for ALK testing diagnostically in Pakistani 
population of Lung Adenocarcinoma which is a common 
type of lung cancer and first line of treatment includes 
the platinum based therapy chemotherapy (Ellison et al., 
2013). However, some patients harboring mutations are 
eligible for the TKIs which provide an advance treatment. 
EGFR is the most commonly mutated gene in such cases 
which accounts for like 60% of the overall cases. Almost 
90% of these mutations are either in-frame deletions of 
exon-19 which removes the amino acids from 747-750 
(LREA) or single nucleotide substitution of thymine to 
guanine resulting in change of arginine from leucine at 858 
position of exon-21 (Shigematsu et al., 2005; Ellison et 
al., 2013). However, according to different published data, 
Figure 2. Bronchial Biopsy Showing Foci of Moderately 
Differentiated Adenocarcinoma of Primary Lung Origin. 
Note diffuse cytoplasmic staining with ALK Protein
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three positive samples in FISH came out to be negative 
in IHC. These results were in agreement with some of the 
studies reported (Eunhee et al., 2011; Paik et al., 2011; 
McLeer-Florin et al., 2012).
To the list of our knowledge this is the first study 
from Pakistan reporting frequency of ALK rearrangement 
in adenocarcinoma of Primary Lung origin as well as 
correlation of FISH results with ALK IHC. Currently, 
the false negative results and less sensitivity do not 
make IHC plausible as primary screening technique. 
This study however, had some limitations which include 
small sample size and IHC testing with only one clone 
of ALK protein. 
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